MPR

First-Line Trodelvy Regimens Approved for Triple-Negative Breast Cancer

Trodelvy is now FDA-approved for first-line treatment of advanced TNBC, significantly improving PFS in phase 3 trials.
MPR

Tryngolza Approved to Reduce Triglycerides and Pancreatitis Risk in sHTG

Tryngolza (olezarsen) is the first approved therapy to significantly lower acute pancreatitis events alongside robust triglyceride reductions in adults with severe hypertriglyceridemia.
MPR

Ibrance Combo Regimen Approved for HR+, HER2+ Advanced Breast Cancer

Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.